Faculty from our Summer Meeting symposium on COVID-19 in the immunocompromised population discuss new information and recommendation updates that have occurred since their initial presentation.
SPEAKERS
Katherine Yang, PharmD, MPH, FCSHP is a Health Sciences Clinical Professor of Pharmacy at the University of California, San Francisco (UCSF) School of Pharmacy and an Infectious Diseases Clinical Pharmacist at the UCSF Medical Center in San Francisco, California. Dr. Yang specializes in the optimization of antibiotic dosing for the treatment of multi-drug resistant gram-negative infections. Since the start of the pandemic, Dr. Yang has been heavily involved in the management of COVID-19 therapeutics at UCSF.
Monica Mahoney, PharmD, BCPS, BCIDP, FCCP is a clinical pharmacy specialist in the outpatient infectious diseases and OPAT clinics at Beth Israel Deaconess Medical Center. Dr. Mahoney received her Pharm.D. degree from MCPHS University Boston. She completed PGY1 and PGY2-ID residencies at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, SIDP, and IDSA.
Michael Ganio, PharmD, MS, BCPS, FASHP joined the staff at ASHP as Director of Pharmacy Practice and Quality in January of 2018. As a member of the Center on Medication Safety and Quality team, his responsibilities span the practice of pharmacy and include drug shortages, pharmaceutical quality, sterile and non-sterile drug compounding practices, hazardous drug handling, and the ASHP Standardize 4 Safety initiative. Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master’s degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Dr. Ganio is a Board Certified Pharmacotherapy Specialist (BCPS) and is a Certified Professional in Healthcare Information and Management Systems (CPHIMS).
Relevant Financial Relationship Disclosures
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.